GoKawiilNovo Nordisk and Eli Lilly present early data linking GLP-1 drugs to slower biological aging clocks
At the ARDD conference at Harvard, Novo Nordisk and Eli Lilly presented preliminary findings suggesting their GLP-1 receptor agonists, including semaglutide, may slow molecular markers of aging. Novo's study of 10,052 participants found proteomic clock differences of about two to three years between drug and placebo groups, with up to a four-year gap on a clock measuring heart-related proteins.
GoKawiil's interpretation of the reporting above, not reported fact.
These are early, company-presented findings rather than peer-reviewed trial results, so the claimed anti-aging effects of GLP-1 drugs remain unconfirmed by independent researchers. If validated, the data could reposition GLP-1 agonists like semaglutide beyond diabetes and weight loss into broader longevity and health-span markets, which would be commercially significant for Novo Nordisk and Eli Lilly. The emphasis on proteomic 'aging clocks' also reflects a wider industry push to use biomarkers as evidence for drug effects beyond traditional disease endpoints.
- Novo Nordisk reported proteomic clock improvements of two to three years, and up to four years for a heart-protein clock, in a 10,052-person study.
- Eli Lilly also presented data at ARDD suggesting GLP-1 drugs may influence biological aging markers.
- The findings are preliminary conference presentations, not peer-reviewed publications, marking the first clinical readouts linking GLP-1 drugs to aging clocks.
Source: trial.medpath.com — Medpath Trial, 2026-10-20
Published there as: “Novo Nordisk, Eli Lilly Report GLP-1 Signals of Slowed Biological Aging at ARDD”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.